Nutreneer is a Swiss health company that transforms patient anamnesis and blood biomarkers into precisely formulated, personalized nutritional supplements. Using its SmartSplit technology, the company distributes individual formulations into morning and evening capsules while accounting for known nutrient interactions, with transparent documentation of composition and dosages. Nutreneer also coordinates customized infusion therapies through licensed partners, available exclusively on medical prescription.
Funding
Funding not disclosed
Founders
Product
Problem
Standard nutritional supplements offer generic, one-size-fits-all formulations that ignore individual biomarker profiles, medical history, lifestyle, and health goals. This approach can lead to ineffective or even counterproductive supplementation, as optimal nutrient needs vary significantly between people and over time. Additionally, conventional processes often lack transparent dosing rationale or fail to adjust formulations as health parameters evolve.
Solution
Nutreneer manufactures personalized capsules in Switzerland, precisely formulated from patient anamnesis and blood values. The company's SmartSplit technology accounts for known nutrient interactions and distributes each individual formulation into separate morning and evening portions for optimal absorption and efficacy. Production occurs in small, quality-assured batches with transparent documentation of composition and dosages. Regular re-checks of relevant biomarkers at quarterly or semi-annual intervals enable targeted adjustments to the AM/PM formulation, keeping supplementation flexible, evidence-based, and aligned with measurable progress.
Target Audience
Primary customers are health-conscious individuals in Switzerland seeking data-driven, personalized supplementation, as well as physicians and medical practices looking for evidence-based nutritional therapy options for their patients.
Features
- SmartSplit technology that divides personalized formulations into morning and evening portions while accounting for known nutrient-nutrient interactions
- Evidence-based formulation process driven by defined biomarkers, structured anamnesis, and fixed decision rules for dosage ranges
- Standardized blood collection options including in-clinic venous draws, on-site service by trained medical practice assistants (MPAs), and the TAP II upper-arm self-sampling device for near-painless at-home collection
- Small-batch manufacturing with documented quality assurance and transparent composition and dosage records
- Dynamic formulation adjustment based on periodic re-checks (typically every 3-6 months) rather than static year-long prescriptions
- Collaboration with licensed partners for standardized and patient-specific infusion therapies, available exclusively on medical prescription